Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734539 · ClinicalTrials.gov registry record · Phase 3
Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight
A Phase 3 study of Candidiasis, sponsored by Daniel Benjamin.
- Completed
- Registry status
- Phase 3
- Development phase
- 362
- Enrollment target
- 20
- Study locations
NCT00734539 is a Phase 3 study of Candidiasis that has completed, run by Daniel Benjamin. The registered enrollment target is 362 participants, above the 279-participant average among 7 other Candidiasis trials with a reported enrollment target (30% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT00734539, a Phase 3 study of Candidiasis, has completed, sponsored by Daniel Benjamin.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 362 participants
- Enrollment target
- 20
- Study locations
Study Summary
The most common etiology of infection-related death or neurodevelopmental impairment in neonates with birthweight \<750 g is invasive candidiasis. Over 70% of the premature neonates who develop invasive candidiasis will die or suffer severe, permanent neurologic impairment. Fluconazole has been commonly used off-label in the neonatal intensive care unit, but definitive recommendations for its use in the nursery have been hampered by the limited number of well-designed trials. In neonates weighing \<750 g, appropriate dosing is not known, definitive safety and long-term follow up trials have not been completed, and there have not been well-powered trials conducted to establish the efficacy of the product using mortality as part of the primary endpoint. Three recent proof-of-concept studies suggest that fluconazole will be safe and effective, and a recently completed pharmacokinetic study is providing data to give preliminary dosing guidance. The next logical step in drug development is proposed by this research: to conduct a pivotal trial to determine the safety and efficacy of fluconazole in premature neonates with 2-year neurodevelopmental follow-up assessment. 362 neonates, with a birthweight \<750g, were randomized at 33 US centers, to twice weekly fluconazole (6 mg/kg) or placebo for the first 6 weeks of life. The primary efficacy endpoint will be Candida-free survival at study day 49. The research will establish definitive dosing, safety, and efficacy of fluconazole; it will also provide critical information on the effects of fluconazole on neurodevelopmental impairment and antifungal resistance. Potential Impact: Approximately 17,000 neonates are born \<750 grams each year in the United States. Over 5000 will die or develop invasive Candida infections. Demonstrating safety and efficacy of fluconazole in preterm neonates will improve the survivability and long term outcomes for these neonates.
Conditions Studied
Interventions
- DRUG placebo
- DRUG fluconazole
Study Locations (20)
Florida
- University of Florida - Gainesville
- Baptist Medical Center - Jacksonville
- Shands Jacksonville Medical Center - Jacksonville
- University of Miami - Miami
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
- Arkansas Childrens Hospital - Little Rock
California
- Children's Hospital of Orange County - Orange
- University of California-San Diego - San Diego
Indiana
- Riley Hospital - Indianapolis
- Memorial Hospital - South Bend
New York
- Brookdale University Medical Center - Brooklyn
- Kings County Hospital Center - Brooklyn
Alabama
- University of Alabama at Birmingham - Birmingham
Kansas
- Wesley Medical Center - Wichita
Kentucky
- Kosair Children's Hospital - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2008-11 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00734539
The ClinicalTrials.gov registry entry for NCT00734539 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 362 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 279-participant average among 7 other Candidiasis trials with a reported enrollment target (30% higher). The listed sponsor is Daniel Benjamin, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Candidiasis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00734539 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT00734539 about?
NCT00734539 is a clinical study titled "Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight". The most common etiology of infection-related death or neurodevelopmental impairment in neonates with birthweight \<750 g is invasive candidiasis. Over 70% of the premature neonates who develop invasive candidiasis will die or suffer severe, permanent neurologic impairment. Fluconazole has been comm...
What is the current status of trial NCT00734539?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 362 participants. The study started on 2008-11. Estimated completion is 2013-04.
What conditions does trial NCT00734539 study?
This clinical trial studies the following conditions: Candidiasis.
What interventions are being tested in trial NCT00734539?
The interventions under investigation include: placebo (DRUG), fluconazole (DRUG).
Who is sponsoring clinical trial NCT00734539?
This trial is sponsored by Daniel Benjamin, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00734539 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Candidiasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
COMPLETED · Phase 3
-
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
COMPLETED · Phase 3
-
A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone
COMPLETED · Phase 1
-
Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants
COMPLETED · Phase 4
-
The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.
COMPLETED · Phase 2
-
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.